Evidence map›Paper›PMID 35887086›Full record

ArticleInternational journal of molecular sciences2022

Tropism of the Novel AAVBR1 Capsid Following Subretinal Delivery.

Lara Carroll, Hironori Uehara, Xiaohui Zhang, Balamurali Ambati

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lara CarrollMoran Eye Center, 65 Mario Capecchi Way, Salt Lake City, UT 84132, USA.ORCID 0000-0002-8232-7386
Hironori UeharaPhil and Penny Knight Campus for Accelerating Scientific Impact, 6231 University of Oregon, Eugene, OR 97403, USA.ORCID 0000-0001-6133-4918
Xiaohui ZhangPhil and Penny Knight Campus for Accelerating Scientific Impact, 6231 University of Oregon, Eugene, OR 97403, USA.
Balamurali AmbatiPhil and Penny Knight Campus for Accelerating Scientific Impact, 6231 University of Oregon, Eugene, OR 97403, USA.
University of Oregon · US

Funding

University of Utah, Core Vision Research GrantP30EY014800 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Bryan William Jones · 2005 to 2026
$14.6M
Intraceptor Interference of VEGF PathwaysR01EY017182 · NEI · UNIVERSITY OF UTAH · PI AMBATI, BALAMURALI K · 2007 to 2017
$3.6M
NEI NIH HHS EY017182NEI NIH HHS P30 EY014800NEI NIH HHS R01 EY017182NIH HHS EY014800Research to Prevent Blindness unrestricted grant
6 · The paper itself

Abstract

A serious limitation of current adeno-associated viral (AAV) capsids employed for subretinal delivery is achieving adequate lateral spread beyond the injection site, required for the efficient delivery of gene therapy to the outer retina and/or RPE. AAVBR1 is a unique AAV with exceptional tropism for CNS microvasculature following systemic delivery. Here, we used in vivo and ex vivo analysis to show that subretinal delivery of AAVBR1.GFP in mice achieves superior tropism to RPE and outer retina than either AAV2.GFP or AAV8.GFP, two of the most common capsids used for subretinal delivery. At a low (5 × 10

Indexed as

CapsidGenetic VectorsAnimalsCapsid ProteinsDependovirusMiceRetinaTransduction, GeneticTropismCapsid Proteinsadeno-associated virus (AAV)binding motifgene therapysubretinal deliverytransduction

Identifiers

PMID35887086
PMCPMC9317317
OpenAlexW4285495995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.